← Back to Search

HMG-CoA reductase inhibitor

Rosuvastatin 20mg for Cardiovascular Disease (DESIFOR Trial)

Phase 4
Waitlist Available
Led By Michael Miedema, MD
Research Sponsored by Minneapolis Heart Institute Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

DESIFOR Trial Summary

This trial will study patients who were unable to tolerate being on a statin medication due to muscle-related side effects to see if they can tolerate the medication after trying it again later.

Eligible Conditions
  • Cardiovascular Disease
  • Cardiovascular Risk
  • Side Effects

DESIFOR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Musculoskeletal intolerance (as documented in study assessments)
Secondary outcome measures
Statin Utilization

Side effects data

From 2015 Phase 3 trial • 20 Patients • NCT02226198
8%
Blood bicarbonate decreased
100%
80%
60%
40%
20%
0%
Study treatment Arm
Maintenance
Lead-in
Cross-over

DESIFOR Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Rosuvastatin 20mgExperimental Treatment1 Intervention
Each participant will receive a 3 month randomly allocated supply of this medication preceded by a 7 day wash-out period.
Group II: No TreatmentActive Control1 Intervention
7 day wash-out period between months
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rosuvastatin 20mg
2013
Completed Phase 4
~1050

Find a Location

Who is running the clinical trial?

Minneapolis Heart Institute FoundationLead Sponsor
29 Previous Clinical Trials
15,440 Total Patients Enrolled
Michael Miedema, MDPrincipal InvestigatorMinneapolis Heart Institute Foundation
1 Previous Clinical Trials
118 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the typical indications for prescribing Rosuvastatin 20mg?

"Rosuvastatin 20mg is regularly administered to treat hypertriglyceridemias, however it can also be utilized to reduce the risk of cardiovascular disease (cvd), and manage the potential impacts of cardiovascular events or surgeries."

Answered by AI

What is the current enrollment limit for this trial?

"This medical trial is not accepting new participants at this time. It was first posted on April 26th 2019, and it's been edited most recently on March 18th 2022. If you're seeking alternative clinical trials, there are currently 486 studies involving cardiovascular conditions actively recruiting, as well as 40 for Rosuvastatin 20mg specifically."

Answered by AI

Are there any open spots for this research project?

"Unfortunately, the recruitment period for this trial has already closed. It was originally posted on April 26th 2019 and last modified on March 18th 2022. If you are seeking other medical trials to participate in, there are 486 cardiovascular related studies that have open enrollment as well as 40 recruiting participants who will take Rosuvastatin 20mg."

Answered by AI

Could taking Rosuvastatin 20mg be a potential hazard to individuals?

"There is a substantial amount of evidence to suggest Rosuvastatin 20mg's efficacy and safety, so it warranted an overall rating of 3."

Answered by AI

Who is eligible to participate in this medical experiment?

"The researchers of this trial seek 25 volunteers aged 21 to 75 with cardiovascular disease, a 10-year ASCVD risk greater than 7.5%, and that are statin intolerant."

Answered by AI

Is this research open to individuals who are over two decades old?

"According to the criteria listed, the ideal participants of this trial must be between 21 and 75 years old. For those under 18 or over 65, there are 31 and 457 trials respectively available for them."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial
2019. "The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03889314.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top